137 related articles for article (PubMed ID: 38240706)
1. Most patients with cancer are not undergoing germline genetic testing.
Fillon M
CA Cancer J Clin; 2024; 74(1):6-7. PubMed ID: 38240706
[No Abstract] [Full Text] [Related]
2. Germline Testing for the Evaluation of Hereditary Cancer Predisposition.
Ceyhan-Birsoy O
Clin Lab Med; 2022 Sep; 42(3):497-506. PubMed ID: 36150826
[TBL] [Abstract][Full Text] [Related]
3. Toward Concurrent Testing for Somatic and Germline Variants in Cancer Patients.
Mandelker D
Clin Cancer Res; 2016 Aug; 22(16):3987-8. PubMed ID: 27307597
[TBL] [Abstract][Full Text] [Related]
4. Do All Patients Diagnosed With Cancer Deserve Germline Testing?
Sorscher S
J Clin Oncol; 2023 Aug; 41(24):4057-4058. PubMed ID: 37311151
[No Abstract] [Full Text] [Related]
5. Yes, We Can, But Should We? Ethical Considerations in Reporting Germline Findings From Paired Tumor-Normal Genomic Testing in Patients With Advanced Cancer.
Hunter CL; Helft PR
J Clin Oncol; 2023 Apr; 41(11):1982-1985. PubMed ID: 36469841
[No Abstract] [Full Text] [Related]
6. "Somatic" Tumor Genomic Profiling and Potential Germline Implications: Ethical Considerations for Children with Cancer.
Knapp E
J Law Med Ethics; 2020 Dec; 48(4):778-783. PubMed ID: 33404327
[No Abstract] [Full Text] [Related]
7. Tumor-Based Genetic Testing and Familial Cancer Risk.
Forman A; Sotelo J
Cold Spring Harb Perspect Med; 2020 Aug; 10(8):. PubMed ID: 31570381
[TBL] [Abstract][Full Text] [Related]
8. The impact of germline testing for hereditary cancer postdiagnosis.
Owens K; Schlager L; Welcsh PL
Am J Manag Care; 2019 Aug; 25(9 Spec No.):SP285-SP287. PubMed ID: 31442012
[No Abstract] [Full Text] [Related]
9. Use of Treatment-Focused Tumor Sequencing to Screen for Germline Cancer Predisposition.
Lau TTY; May CM; Sefid Dashti ZJ; Swanson L; Starks ER; Parker JDK; Moore RA; Tucker T; Bosdet I; Young SS; Santos JL; Compton K; Heidary N; Hoang L; Schrader KA; Sun S; Kwon JS; Tinker AV; Karsan A
J Mol Diagn; 2021 Sep; 23(9):1145-1158. PubMed ID: 34197922
[TBL] [Abstract][Full Text] [Related]
10. Pediatric cancer genetics.
Dean SJ; Farmer M
Curr Opin Pediatr; 2017 Dec; 29(6):629-633. PubMed ID: 28984800
[TBL] [Abstract][Full Text] [Related]
11. When to use germline genetic testing in prostate cancer.
Giri VN
Clin Adv Hematol Oncol; 2022 Feb; 20(2):78-81. PubMed ID: 35120087
[No Abstract] [Full Text] [Related]
12. When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?
DeLeonardis K; Hogan L; Cannistra SA; Rangachari D; Tung N
J Oncol Pract; 2019 Sep; 15(9):465-473. PubMed ID: 31509718
[TBL] [Abstract][Full Text] [Related]
13. Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer:
Subbiah V; Kurzrock R
J Clin Oncol; 2023 Jun; 41(17):3100-3103. PubMed ID: 36930859
[No Abstract] [Full Text] [Related]
14. Population Frequency of Germline BRCA1/2 Mutations.
Maxwell KN; Domchek SM; Nathanson KL; Robson ME
J Clin Oncol; 2016 Dec; 34(34):4183-4185. PubMed ID: 27551127
[No Abstract] [Full Text] [Related]
15. The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?
Liu YL; Stadler ZK
J Natl Compr Canc Netw; 2021 Jul; 19(7):871-878. PubMed ID: 34340209
[TBL] [Abstract][Full Text] [Related]
16. Speaking genomics to parents offered germline testing for cancer predisposition: Use of a 2-visit consent model.
Johnson LM; Sykes AD; Lu Z; Valdez JM; Gattuso J; Gerhardt E; Hamilton KV; Harrison LW; Hines-Dowell SJ; Jurbergs N; McGee RB; Nuccio R; Ouma AA; Pritchard M; Quinn EA; Baker JN; Mandrell BN; Nichols KE
Cancer; 2019 Jul; 125(14):2455-2464. PubMed ID: 30901077
[TBL] [Abstract][Full Text] [Related]
17. Tumor Genomic Testing: Identifying Characteristics Associated With Germline Risk for Developing Malignancy.
Mahon SM
Clin J Oncol Nurs; 2020 Dec; 24(6):623-626. PubMed ID: 33216058
[TBL] [Abstract][Full Text] [Related]
18. Tailoring cancer treatment using germline cancer genetics - are we almost there?
Mitchell G
Clin Oncol (R Coll Radiol); 2009 Aug; 21(6):441-3. PubMed ID: 19591774
[No Abstract] [Full Text] [Related]
19. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
[TBL] [Abstract][Full Text] [Related]
20. Universal Genetic Testing to Identify Pathogenic Germline Variants in Patients With Cancer.
Colas C; De Pauw A; Golmard L
JAMA Oncol; 2021 Jul; 7(7):1071. PubMed ID: 34014284
[No Abstract] [Full Text] [Related]
[Next] [New Search]
